Table 1:

Patient characteristics

Patients, n (%)	40 (100)
Age at study entry, median (range)	42 (16–67)
Gender, female, n (%)	20 (50)
Phase of chronic myeloid leukemia at HCT, n (%)
Chronic	27 (67.5)
Accelerated	10 (25)
Blast crisis in complete hematologic remission	3 (7.5)
Donor type, n (%)
Matched related	18 (45)
Matched unrelated	13 (32.5)
Mismatched related	4 (10)
Mismatched unrelated	5 (12.5)
Graft source, n (%)
Bone Marrow	38 (95)
Peripheral blood stem cells	2 (5)
Conditioning regimen, n (%)
Total body irradiation + cyclophosphamide	22 (55)
Busulfan + cyclophosphamide	18 (45)
GvHD prophylactic regimen, n (%)
Methotrexate + calcineurin inhibitor	40 (100)
Anti-thymocyte globulin	4 (10)
Months from HCT to molecular relapse, median (range)	6.3 (5.6–13.6)
Complete cytogenetic remission at enrollment, n (%)	40 (100)
Use of TKIs prior to enrollment, n (%)	0
Use of IFN prior to transplant, n (%)	19 (47.5)